US FDA approves Pfizer's intravenous Revatio
This article was originally published in Scrip
Executive Summary
The US FDA has approved an intravenous formulation of Pfizer's Revatio (sildenafil; also known as Viagra) for the treatment of pulmonary arterial hypertension (PAH). With this approval, Revatio becomes the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations, says the company.